Research-based leading Biotech company, Cinclus Pharma, has announced on Thursday that it has appointed new Chief Financial Officer (CFO) Jenni Björnulfson to regulate the finance-based operations of the company.
According to the PR News Wire News Agency, the newly appointed CFO Jenni Björnulfson has extensive professional experience in the healthcare sector and financial markets. Apart from that, Jenni has also got years of experience in managing corporate finance with the ABN AMRO and Handeisbanken Markets.
The newly appointed Chief Financial Officer Jenni has got the degree from the Stockholm School of Economics. Previously, Jenni has served as the CFO for Promore Pharma AB since 2016
It is important to mention that Jenni will initially join the company on a part time basis, before joining full time later in 2020.
CEO Cinclus Pharma, Kjell Andersson, said, “We are delighted to welcome Jenni to Cinclus Pharma’s expanding Management team and we value that she is bringing her expertise and experience to the company at an exciting time following our recent successful financing round”.
Earlier on March 4, the Pharma has previously announced that it had successfully provided SEK 250 million funds for the clinical development of X842, a clinical-based drug formulated for the treatment of gastroesophageal reflux disease (GERD). The X842 drug has the potential to heal the esophageal injuries and gastroesophageal reflux disease (GERD) more efficiently than any other drug currently available in the market.
It is important to mention that gastroesophageal reflux disease (GERD) is basically can be simplified as a condition by puking of gastric acid from the stomach of the patient into esophagus. This symptom can lead to mucosal erosions and severe pain, which is sometimes unbearable for the patient.
Currently, all the treatment and medical remedies available in the market are not sufficiently effective to maintain normal and constant pH of patients for a full day. The best treatment available in the market to heal the gastroesophageal reflux disease (GERD) is the use of PPIs such as Nexium or Losec, which don’t always deliver 100% satisfactory results as about 40% patients complained of unsatisfactory symptom alleviation.
On the other hand, the X842 drug utilizes the entirely different mode of action for the control and release of gastric acid, as compared to the Proton Pump Inhibitors or PPIs.
Sam Leventhal is a self-taught investor and follows the value investing approach to picking stocks. He possesses over 10 years of investment experience, an M.B.A. from Louisiana State University, and is also certified in Risk Management Assurance. Sam is a Certified Internal Auditor, Data Miner, and author with a career broadly spanning over multiple business areas. He has exploited those observations and developed investment tactics within a fundamentally sound long-term investment strategy. He currently covers Technology News category for our site.
Email Contact – [email protected]
Address: 1894 MacLaren Street, Ottawa, Ontario
Zip Code: K1P 5M7
Phone Number: 613-785-7363